InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Allied Healthcare Products, Inc. is a leading manufacturer of medical gas construc...
Allied Healthcare Products, Inc. is a leading m...
Aldeyra Therapeutics is a biotechnology company devoted to developing and commerci...
Aldeyra Therapeutics is a biotechnology company...
MedChain's mission is to use blockchain technology to establish a better, more sec...
MedChain's mission is to use blockchain technol...
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company ...
Iterum Therapeutics plc is an Ireland-based cli...
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-i...
Aerpio Pharmaceuticals is a biopharmaceutical c...
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercializa...
Soleno Therapeutics, Inc. (Soleno) is focused o...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Join the National Investor Network and get the latest information with your interests in mind.